Continuing Medical Education Grants and Sponsorships Name of Recipient Horizon CME, Inc.

Medtelligence, LLC

Clinical and Patient Educators Association

Rectors and Visitors of the University of Virginia

Clinical and Patient Educators Association

American College of Cardiology Foundation

Program Name

Program Description

Individualizing Anticoagulation A series of 8 live, 60-minute grand rounds to be presented at Therapy to Reduce Bleeding and hospitals and clinics throughout the US and targeted toward Stroke Risk in Patients with AF: A PCPs, hospitalists, NPs and PAs who practice in a primary Dual-Focused Educational Initiative care setting. for Health Care Professionals & Patients Managing Today’s EP Challenges Interactive CME activity provides an opportunity for specialist With NOAC Use clinicians to evaluate the clinical value of recent large-scale randomized clinical trials on stroke prevention in patients with atrial fibrillation (AF) who are managed with various interventions. Target-Specific Oral Panel of 4 expert national level thought leaders with research Anticoagulation in Clinical Practice: and clinical experience regarding management of Breaking News, thrombosis, and to impart information about the practical Contemporary Views and appropriate use of the newest target-specific oral anticoagulants. Ensuring Appropriate Use of Educational activity will be comprised of an interactive 'virtual Newer Anticoagulants: Preventing patient' consult where the learner will have the ability to Stroke in Patients view the patient’s chart, medical history, tests, and suggest with Nonvalvular Atrial Fibrillation the appropriate use of anticoagulants. Hospitalists on the Frontline: Preventing and Managing Thromboembolic Events

A panel of 4 expert national-level thought leaders to conduct a 2-hour live, interactive continuing medical education (CME) satellite symposium, and a Web Monograph developed from the proceedings of the live symposiums. Why is Stroke Prevention in AF So A comprehensive overview of practical issues with regards to Difficult? Live Clinical Focus managing the risk for thromboembolism and bleeding in Session at ACC.15 patients with atrial fibrillation and various risk factors.

Amount $30,000

$113,793

$80,000

$44,450

$52,000

$25,000

1

Continuing Medical Education Grants and Sponsorships Name of Recipient

Program Name

Program Description

Amount

Medical Learning Institute Inc.

NOACS: What the Evidence Shows in Managing AFib, Stroke Prevention, and DVT/PE

A series of five CME-certified immersive learning workshops focused on the current clinical strategies associated with the management of AFib and DVT/PE

$100,000

Duke University, School of Medicine

Bridging the Gaps: A PatientCentered Approach to Selecting Novel Oral Anticoagulants

Hospital-based clinicians face the everyday challenge of providing individualized, safe, and effective care for patients with atrial fibrillation (AF).

$85,000

American College of Emergency Physicians

Managing Thromboembolic Disease Evolving Strategies for Prophylaxis and Treatment of Active Disease

Gaps exist between recommendations and clinical practice, and many patients are unnecessarily exposed to the risk of DVT or potentially fatal PE. This program is designed to address ACGME and IOM competencies, including delivering patient-centered care, practicing evidence-based medicine, and focusing on quality improvement.

$40,000

American College of Chest Physicians

What's New in Venous Thromboembolism

The American College of Chest Physicians (CHEST) requests support for an educational track (STEP) at CHEST 2015 consisting of: •Morning educational symposium (MES) – CME •Small case-based interactive discussion (SCID) – CME •Self-study station (SSS) – CME •Posting of the MES presentations for one year – non-CME •Posting of the SSS module available to CHEST attendees for two additional months– CME.

$30,000

University of Massachusetts Medical School

Practical, Evidence-Based and Patient-Centric Strategies for Optimizing Anticoagulation-Based Interventions in Patients With NVAF and VTE

The program will focus on evidence, guidelines, authoritative consultation, and landmark clinical trials; and, how this body of rapidly evolving evidence and expert, consensus-based analysis—in the areas of VTE treatment and stroke prevention in AF—can be translated to the front lines of cardiovascular, hospital-based, thrombosis-focused, EM, hospital-based, and internal medicine specialty practice.

$150,000

2

Continuing Medical Education Grants and Sponsorships Name of Recipient USF Health Professions Conferencing Corporation

Medscape Education, LLC

University of Kentucky

Program Name

Program Description

Stroke Prevention in Atrial atPoint of Care is a mobile and web CME clinical decisionFibrillation & Venous making platform that Thromboembolism @Point of Care integrates a clinician learning platform and patient companion app. We provide a streamlined solution for clinicians to obtain clinically relevant, scientifically rigorous CME-certified content when and where it is needed most to improve clinician and patient outcomes. Throbbing Topics in Thrombosis A multi-supported live symposium at the annual meeting of American Society of Hematology (Dec 2015). An enduring program will also be developed. Optimal Anticoagulation Therapy: A Prescription for Improvement

Content development via teleconference. A steering committee of 3 national-level clinical pharmacy experts with research and clinical expertise in the area of thrombosis management will be convened to develop the content for the initiative. Content development is anticipated to begin in April 2015 or immediately following grant funding approval. A series of 20 live continuing pharmacy education (CPE) symposia to be held in alignment with meetings of regional, state, and local-level chapters of professional pharmacy associations, including the American Society of Health System Pharmacists (ASHP) and institutional and state pharmacy associations. The meetings will be implemented between July 2015 and July 2016. We anticipate an average of 75 learners will attend each meeting.

Amount $50,000

$100,000

$75,000

3

Continuing Medical Education Grants and Sponsorships Name of Recipient Clinical and Patient Educators Association

Program Name ACTION: AntiCoagulation Treatment Strategies—Insights to Optimize Application of the Evidence in Practice: An NOAC Update—Having Local Impact

Pharmacy Times Office of Dissecting Venous Continuing Professional Education Thromboembolism: A Focus on New Oral Anticoagulants and Successful Pharmacy-Based Prevention Strategies

Heart Rhythm Society, Inc.

CC69: Emerging Indications for Novel Anticoagulants: New Advances and Treatment Dilemmas

Program Description

Amount

•Remote content development via teleconference. A steering committee of national level thought leaders with research and clinical experience in thrombosis management will be convened to develop the content for the initiative. Content development is anticipated to begin in March 2015 or immediately following the grant approval and steering committee recruitment. •75 CME/CPE-certified in-hospital grand rounds. These 1hour grand rounds activities, led by 1 national expert faculty presenter, will include didactic lecture, real world case study presentation(s) led by a second, local faculty member, also an expert in the field of thrombosis, with commentary from the national faculty member and a brief question-and-answer session. The grand rounds series will take place from June 2015 through September 2016. We anticipate approximately 55 participants per grand rounds activity, for a total of 4125. The in-book article will be printed in Pharmacy Times (Health System Edition). These publications are distributed to 193,000 subscribers of which 29,000 have identified themselves as health system pharmacists. The remaining 164,000 are community, long term care, ambulatory and consultant pharmacists. The in-book will be converted into an online article and be available on www.pharmacytimes.org to the over 166,000 monthly online users for up to 1 year. The patient case will be posted online at www.pharmacytimes.org for up to 1 year as well. What are the benefits and limitations of novel anticoagulants (NOACs) for common clinical problems encountered in EP practice? Learn how to use NOACs in patients undergoing cardioversion, device implantation, ablation and percutaneous coronary intervention and find out if NOAC resistant patients can be identified.

$75,000

$25,000

$15,000

4

Continuing Medical Education Grants and Sponsorships Name of Recipient MediaSphere Medical, LLC

Program Name The Symposium on Stroke Prevention in Atrial Fibrillation Advancement in Novel Oral Anticoagulation Therapy and LAA Closure

Program Description

Amount

The activity has been developed to enhance the global clinician community about advancements in novel oral anticoagulation therapy and non-pharmacoloigcal options for managing stroke in AF patients. A need exists to evaluate current limitations in traditional therapy, and assess emerging therapeutic approaches in NOAC therapy and adjudicative interventional approaches for the management of systemic thromboembolism. AF is an independent predictor of stroke, with an annual risk that is 5 to 6 times higher than patients in sinus rhythm. However, this risk is not homogeneous, ranging from an annual risk of 1% in patients aged over 65 years old with no risk factors, to over 12% per year in patients who have a history of prior stroke, transient ischemic attack. Not only is AF a major risk factor for stroke, but when strokes occur in association with AF, the patients suffer substantial mortality, morbidity, disability and longer hospital stays compared with stroke patients without AF. The benefits of thromboprophylaxis in patients with AF are well established in randomized trials, and most guidelines recommend the use of anticoagulation with warfarin for highrisk patients. However, there continues to be wide variation in management. In particular, the elderly are at the highest risk of stroke, and would benefit most from thromboprophylaxis. However, the elderly have more comorbidities and concomitant therapies that may preclude anticoagulant therapy. Also, most of the evidence on thromboprophylaxis has been based on hospital-managed populations. While Warfarin reduces the risk of stroke in patients with AF, it increases the risk of hemorrhage and is difficult to use, consequently, the emerging of novel oral anticoagulation therapy is a promising paradigm shift in standard of care. An activity has been developed to improve professional competence, performance, and patient outcomes in the management of stroke in AF patients.

$50,000

5

Continuing Medical Education Grants and Sponsorships Name of Recipient SMBD Jewish General Hospital

International Association for the Study of Lung Cancer (IASLC) University of Florida

Program Name

Program Description

Amount

To generate new knowledge through research innovation of VTE researchers in Canada to discover causes and to improve prevention and treatment of VTE and related disorders. IASLC Fellowship & IASLC Young 1 year fellowship to younger fellows to keep interest for lung Investigators Awards cancer research

$100,000

Vascular Biology Working Group Global Chapter Meeting

$20,000

CanVECTOR

The objective of the conference is to provide attendees an important update on the new science shaping the practice of cardiovascular medicine and to provide an opportunity for high-level discussion of the data presented. PVI-PeerView Institute for Medical An Expanding Role for Novel Oral A series of concise, interactive audio-visual presentation Education Anticoagulants: New Opportunities modules featuring a cardiology expert reviewing important to Individualize Prevention of evidence on the prevention of thromboembolic events in Thromboembolic Events in patients with atrial fibrillation. Patients With Atrial Fibrillation St. John’s University, College of Pharmaceutical Industry Pharmaceutical Industry Fellowship in Regulatory/Clinical Pharmacy and Health Sciences Fellowship in Regulatory/Clinical Affairs Affairs University of Florida Educational Grant Agreement This funding is to support and train an Assistant Clinical Research Professor (non-tenured) or a three year Postdoctoral Fellow in pharmacometrics and system pharmacology through focused translational research projects developed jointly by CPSP Faculty and DSI to address pressing problems or issues important to the drug development process of the sponsoring company either now or in the anticipated future. Research Associates PK/PD Modeling and Systems This funding is in support of training and research activities in Analysis the laboratory of Professor Donald E. Mager at the University of Buffalo

$43,000

$40,000

$76,975

$50,000

$16,667

6